Windlas Biotech Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Komal Gupta
Chief executive officer
₹21.3m
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 10yrs |
| CEO ownership | n/a |
| Management average tenure | 5.5yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
It Looks Like The CEO Of Windlas Biotech Limited (NSE:WINDLAS) May Be Underpaid Compared To Peers
Jul 22
Should You Be Adding Windlas Biotech (NSE:WINDLAS) To Your Watchlist Today?
Mar 25What You Can Learn From Windlas Biotech Limited's (NSE:WINDLAS) P/E After Its 28% Share Price Crash
Feb 19Windlas Biotech (NSE:WINDLAS) Seems To Use Debt Quite Sensibly
Jan 28There May Be Underlying Issues With The Quality Of Windlas Biotech's (NSE:WINDLAS) Earnings
Nov 20Windlas Biotech Limited's (NSE:WINDLAS) 30% Share Price Surge Not Quite Adding Up
Nov 01Windlas Biotech (NSE:WINDLAS) Will Pay A Larger Dividend Than Last Year At ₹5.50
Sep 01Windlas Biotech Limited (NSE:WINDLAS) Stock Rockets 26% But Many Are Still Ignoring The Company
Aug 13Should You Be Adding Windlas Biotech (NSE:WINDLAS) To Your Watchlist Today?
Jul 30Even With A 27% Surge, Cautious Investors Are Not Rewarding Windlas Biotech Limited's (NSE:WINDLAS) Performance Completely
Jun 07Is Now The Time To Put Windlas Biotech (NSE:WINDLAS) On Your Watchlist?
Nov 03Windlas Biotech (NSE:WINDLAS) Is Increasing Its Dividend To ₹4.00
Aug 20Windlas Biotech (NSE:WINDLAS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
May 23Windlas Biotech Limited's (NSE:WINDLAS) Shares Lagging The Market But So Is The Business
Apr 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | ₹652m |
| Mar 31 2025 | ₹21m | ₹21m | ₹610m |
| Dec 31 2024 | n/a | n/a | ₹617m |
| Sep 30 2024 | n/a | n/a | ₹612m |
| Jun 30 2024 | n/a | n/a | ₹596m |
| Mar 31 2024 | ₹17m | ₹17m | ₹582m |
| Dec 31 2023 | n/a | n/a | ₹526m |
| Sep 30 2023 | n/a | n/a | ₹467m |
| Jun 30 2023 | n/a | n/a | ₹449m |
| Mar 31 2023 | ₹11m | n/a | ₹426m |
Compensation vs Market: Komal's total compensation ($USD239.52K) is about average for companies of similar size in the Indian market ($USD186.19K).
Compensation vs Earnings: Komal's compensation has increased by more than 20% in the past year.
CEO
Komal Gupta
Mrs. Komal Gupta is the Chief Financial Officer of Windlas Biotech Limited since October 16, 2015 and serves as its Chief Executive Officer since February 08, 2023. She joined Windlas Biotech on October 16...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & CEO | 10yrs | ₹21.26m | no data | |
| Company Secretary & Compliance Officer | 4.5yrs | ₹3.01m | no data | |
| Whole-Time Director | no data | ₹15.60m | 62.34% ₹ 12.3b | |
| MD & Executive Director | 5.5yrs | ₹17.70m | 0.000010% ₹ 2.0k | |
| Joint MD & Executive Director | 5.5yrs | ₹17.70m | 0.000030% ₹ 5.9k | |
| Executive Director | no data | ₹8.46m | no data | |
| President of Sales & Marketing | no data | no data | no data | |
| Site Quality Head | 5.8yrs | no data | no data |
Experienced Management: WINDLAS's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Whole-Time Director | 24.7yrs | ₹15.60m | 62.34% ₹ 12.3b | |
| MD & Executive Director | 17.8yrs | ₹17.70m | 0.000010% ₹ 2.0k | |
| Joint MD & Executive Director | 19.5yrs | ₹17.70m | 0.000030% ₹ 5.9k | |
| Executive Director | 6.3yrs | ₹8.46m | no data | |
| Non-Executive Independent Director | 4.4yrs | ₹550.00k | no data | |
| Non-Executive Independent Chairman | 4.4yrs | ₹340.00k | no data | |
| Non-Executive Independent Director | 4.4yrs | ₹410.00k | no data | |
| Non-Executive Director | 4.4yrs | no data | 0.000010% ₹ 2.0k |
Experienced Board: WINDLAS's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 14:24 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Windlas Biotech Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.